X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Tops Revenue Estimates
X4 Pharmaceuticals: Q3 Earnings Snapshot
X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals Q3 EPS $(0.16) Beats $(0.19) Estimate, Sales $2.879M Beat $2.300M Estimate
X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day - Slideshow
X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day Transcript
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
FDA Provides Orphan Drug Designation To X4 Pharmaceuticals' Mavorixafor To Treat Congenital
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade)
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.